Defined human Clostridia consortia reverse colitis via dual effects of tryptophan metabolites on microbiota and immunity
Cell Host & Microbe · 2026-09 · 34 (9) · 1746-1763.e15
DOI: 10.1016/j.chom.2026.08.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Host & Microbe, 2026-09. Verfasst von Akihiko Oka und 20 weiteren Autor:innen. Beteiligte Einrichtung: Center for Gastrointestinal Biology and Disease, Department of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina at…. Hauptthemen laut MEDLINE: Colitis, Tryptophan, Clostridium, Microbiota. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 147 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Microbial dysbiosis and disrupted mucosal immune homeostasis are integrally involved in the pathogenesis of inflammatory bowel diseases (IBDs). Live biotherapeutic products (LBPs) offer a potential therapeutic strategy to restore beneficial microbes and mitigate disease. We investigated the therapeutic efficacy of 2 LBPs, human Clostridia consortia 17-mix and 11-mix, by treating established colitis in murine models. Both LBPs exhibited therapeutic effects in T cell-mediated chronic colitis models induced by human microbiota and in pathobiont-driven gnotobiotic colitis models established with combinations of IBD-relevant human-derived strains. Metagenomic and metabolomic analyses elucidated mechanisms that go beyond established functions driven by short-chain fatty acids (SCFAs) and interleukin (IL)-10-producing regulatory T cells. Notably, LBPs exerted therapeutic effects by directly inhibiting resident pathobionts and through IL-10-independent activation of host anti-inflammatory aryl hydrocarbon receptor (AhR) pathways by bacterial tryptophan metabolites. These results elucidate SCFA- and IL-10-independent protective mechanisms exerted by defined resident bacterial strains that are depleted in IBD dysbiosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Gastrointestinal Biology and Disease, Department of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Internal Medic…
- Johnson & Johnson, Spring House, PA 19477, USA.
- Center for Gastrointestinal Biology and Disease, Department of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
- The National Gnotobiotic Rodent Resource Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
- Center for Gastrointestinal Biology and Disease, Department of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Microbiology a…
- Center for Gastrointestinal Biology and Disease, Department of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Digestive Disease Institute,…
Förderung
- NIDDK NIH HHS
- NIH HHS
- NIAID NIH HHS
- National Institutes of Health
- Foundation for the National Institutes of Health
- Crohn's & Colitis Foundation
- AMED
- Japan Science and Technology Agency Strategic Basic Research Programs
Zitieren
APA
Oka, A., Bongers, G., Mishima, Y., Baltus, A. J., Gray, S. M., Liu, B., Herzog, J. W., Benedetto, J. R., Fan, T. J., Jang, J., Awoniyi, M., Rousta, E., Hao, L. Y., Gharaibeh, R. Z., Fodor, A. A., Ohkusa, T., Atarashi, K., Fukuda, S., Honda, K., …, & Sartor, R. B. (2026). Defined human Clostridia consortia reverse colitis via dual effects of tryptophan metabolites on microbiota and immunity. Cell Host & Microbe, 34(9), 1746-1763.e15. https://doi.org/10.1016/j.chom.2026.08.003
Vancouver
Oka A, Bongers G, Mishima Y, Baltus AJ, Gray SM, Liu B, et al. Defined human Clostridia consortia reverse colitis via dual effects of tryptophan metabolites on microbiota and immunity. Cell Host & Microbe. 2026;34(9):1746-1763.e15. doi:10.1016/j.chom.2026.08.003
BibTeX
@article{Oka2026,
author = {Oka, Akihiko and Bongers, Gerold and Mishima, Yoshiyuki and Baltus, Andrew J and Gray, Simon M and Liu, Bo and Herzog, Jeremy W and Benedetto, John R and Fan, Ting-Jia and Jang, Jisun and Awoniyi, Muyiwa and Rousta, Esmat and Hao, Ling-Yang and Gharaibeh, Raad Z and Fodor, Anthony A and Ohkusa, Toshifumi and Atarashi, Koji and Fukuda, Shinji and Honda, Kenya and San Mateo, Lani R and Sartor, R Balfour},
title = {Defined human Clostridia consortia reverse colitis via dual effects of tryptophan metabolites on microbiota and immunity},
journal = {Cell Host & Microbe},
year = {2026},
volume = {34},
number = {9},
pages = {1746--1763.e15},
doi = {10.1016/j.chom.2026.08.003}
}
EUVIMED